Massive Bio

Our Co-Founder and CEO Selin Kurnaz, PhD was in #Nashville for the AGC Partners HCIT & Life Sciences Technology Summit, with 16 investor meetings in a single day. The investment landscape for healthcare AI is shifting. Traditional software models are being re-evaluated, consolidation is on the horizon, and the platforms that own a vertical with direct patient-consented data at their core are the ones positioned to lead. Massive Bio is at the center of that shift. Hear Selin's take on what investors are signaling and what it means for the road ahead, and visit massivebio.com/asco26 to see what Massive Bio is bringing to #ASCO2026 and schedule a meeting. #HealthcareAI #Oncology #ClinicalTrials #HealthTech #PrecisionOncology #ASCO2026 #ASCO26

Massive Bio and Just Worldwide are partnering to connect more cancer patients to clinical trial opportunities — through patient communities, advocacy groups, and AI-driven trial matching. Only 3–5% of cancer patients ever enroll in a clinical trial. The barrier is rarely eligibility. It is awareness, access, and trust. Just Worldwide brings deep engagement with patient communities — including underrepresented populations — at a scale that traditional recruitment methods cannot reach. Massive Bio brings the AI infrastructure to match those patients to the right trials at the right moment. Together, we are closing the gap between patients who qualify and trials that need them. "As oncologists, we know that the right clinical trial can be a turning point for a patient — but only if they know it exists. Just Worldwide's ability to engage patients and advocacy communities at scale, combined with Massive Bio's AI matching engine, creates a system where the right information finds the right patient at exactly the right moment in their journey." — Arturo Loaiza-Bonilla, MD, Co-Founder & Chief Medical AI Officer, Massive Bio 🔗 massivebio.com/massive-bio-ju… @MassiveBio @JWWMedResearch @DrArturoAI #ClinicalTrials #Oncology #AIinOncology #CancerCare #PatientAccess #HealthEquity #PrecisionOncology

Happy Mother's Day to every mom out there. 💙 The ones who stayed up late worrying. The ones who fought battles no one saw. The ones who kept goin, no matter what. At Massive Bio, we think of mothers every day. They're why we work to make sure no cancer patient runs out of options. #MothersDay #MassiveBio #CancerCare #ClinicalTrials #HappyMothersDay

Massive Bio was featured in Genetic Engineering & Biotechnology News (@GENbio) as part of a deep dive into how AI is reshaping drug discovery and clinical research. The piece covers a broader shift: big tech is building AI platforms purpose-built for scientific workflows. The inference inflection has arrived in biopharma. For us, this reinforces what we've been building, AI-driven infrastructure that matches cancer patients to clinical trials with the speed and rigor oncology demands. 🔗: genengnews.com/topics/artific…

As AI reshapes healthcare, one of its most meaningful impacts is breaking down barriers to access — ensuring the right patients can find the right treatments at the right time. @MassiveBio's partnership with @OpenAI is a powerful step in that direction. By transforming complex clinical trial protocols into machine-readable formats, the team is enabling real-time, automated patient pre-screening at scale. "By collaborating with OpenAI, we are transforming how trials are interpreted and operationalized. This is infrastructure-level deployment that can close the gap between the thousands of open trials and the millions of patients who never learn they may qualify." — Co-founder & Chief Medical AI Officer Arturo LoAIza-Bonilla MD. Read the full story: lnkd.in/gBEZAJv2 @christine_tsai @TonyW @vishalharnal @atxfrench @leoclee

What does it actually take to rewire health delivery at scale, not just regionally, but globally? Our Co-Founder & Chief Medical AI Officer, Dr. Arturo LoAIza-Bonilla MD (@DrArturoAI), joined Fern Lazar (@fernlazar) at the @1businessworld Global Health & Purpose Summit to tackle exactly that. In their session "From Innovation to Impact: Rewiring Global and Regional Health Delivery at Scale," Arturo and Fern explored how AI-driven precision oncology is bridging the gap between breakthrough innovation and real-world patient outcomes, across borders, healthcare systems, and clinical realities. At @MassiveBio, that's not a vision statement. It's what we build every day. 🎥 Watch the full session → massivebio.com/from-innovatio… #GlobalHealth #PrecisionOncology #HealthcareAI #ClinicalTrials

Our Co-Founder & Chief Medical AI Officer Dr. Arturo LoAIza-Bonilla MD (@DrArturoAI) joins leading voices in #hematologic #oncology in this Society of Hematologic Oncology (SOHO) Insider piece on a critical challenge: gaps in patient representation can make even strong trial results harder to apply broadly. It's a conversation the field needs to keep having. 🔗 sohoinsider.com/news/when-us-r… #ClinicalTrials #Oncology #PatientAccess

@MassiveBio and @OpenAI are converting complex oncology and hematology eligibility criteria into structured parameters for real-time patient pre-screening. This collaboration targets one of BigPharma's enduring challenges ... matching patients to clinical trials quickly enough to affect treatment options. 🔗hlth.com/insights/news/… #NewMedsMatter

@MassiveBio is collaborating with @OpenAI to expand global access to clinical trials. 🌍 Through our collaboration with @OpenAI, we're enabling real-time trial parameterization and free pre-screening services in high-population regions, ensuring that life-changing opportunities are available to patients everywhere, not just those near major research centers. This is what AI-driven precision oncology looks like in practice: breaking down the barriers that have long kept underserved patients from accessing the trials that could change their lives. Read the full announcement → massivebio.com/massive-bio-ex… #ClinicalTrials #AIinHealthcare #PrecisionOncology #HealthEquity #CancerResearch #OpenAI #DigitalHealth

Before ASCO, make sure you are caught up: massivebio.com/massive-bio-pu…

Massive Bio is heading to American Society of Clinical Oncology (ASCO) 2026 and we could not be more ready. May 29 – June 2 | McCormick Place, Chicago | Booth #IH04 ASCO is where the oncology world comes together, researchers, clinicians, pharma leaders, and patient advocates, all in one place, all working toward the same goal: better outcomes for cancer patients. This year, we are bringing our most advanced technology to the floor. Stop by Booth #IH04 to get a live demo of Trial Relay, our AI-powered platform that connects cancer patients to the right clinical trial in real time. See NexusPulse™ in action, the real-time AI signal engine powering smarter oncology decisions. And meet the team that has been quietly building one of the most impactful platforms in precision oncology. Whether you are a #clinician, #researcher, #pharmapartner, or #patientadvocate, there is something at our booth for you. Attending ASCO this year? Drop a comment below or send us a message. We would love to set up time to connect. See you in Chicago. #ASCO26 #ClinicalTrials #AIinOncology #PrecisionOncology #Oncology #CancerResearch #Chicago

Our prospective study, published in ESMO Real World Data & Digital Oncology, has now been featured by American Society of Clinical Oncology (@ASCO) AI in Oncology. The recognition keeps coming. From peer-reviewed publication to editorial coverage by an ASCO-affiliated platform, the validation of Neuro-symbolic, Multi-agent AI in oncology clinical trial matching continues to grow. 3,804 patients. F1 = 0.82. 4x faster matching. Two leading oncology publications now pointing to the same conclusion: this architecture works at scale, in real clinical practice, with auditable results. 🔗 ascoai.org/articles/2026/… #AIinOncology #ClinicalTrials #PrecisionOncology #oncology #AI #cancerresearch #healthcareAI

The gap between cancer patients and clinical trials has always been an access problem. On April 28, we are announcing a collaboration that changes this at a scale never seen before. Can you guess who we are collaborating with? 👇 #ClinicalTrials #HealthcareAI #Oncology #DigitalHealth #PatientAccess

We brought together pioneers, survivors, and innovators in Dallas with one shared belief: every cancer patient deserves access to the right clinical trial. The full Massively Insightful Summit recordings are live. Every panel. Every speaker. Every moment. 🎥 Watch: youtube.com/playlist?list=… #oncology #clinicaltrials #cancer

Massive Bio has earned the DiMe Seal and is now listed in the CMS Medicare App Library, connecting cancer patients to AI-driven clinical trial matching through a federally recognized channel. #DiMeSeal #Oncology #DigitalHealth #CancerCare

Massive Bio has earned the DiMe Seal and is now listed in the CMS Medicare App Library. The DiMe Seal, issued by the Digital Medicine Society (DiMe), is an independent quality certification that evaluates digital health applications across clinical evidence, privacy and security, usability, and interoperability. As of February 2026, CMS designated the DiMe Seal as the required credential for entry into the Medicare App Library, a federal marketplace serving more than 68 million Medicare beneficiaries. For Massive Bio, this means our platform has been independently verified to meet the highest standards in digital health, and is now accessible through a federally recognized channel to Medicare beneficiaries across the United States. We remain committed to building infrastructure that cancer patients, healthcare providers, and clinical trial sponsors can trust. Learn more: massivebio.com #CancerCare #DigitalHealth #ClinicalTrials #DiMeSeal #MedicareAppLibrary #Oncology #HealthTech #AIinHealthcare

Last week, Çağatay Çulcuoğlu and Nick Anderson, Oncology Provider Account Manager, met with @LSUHealthNO, @LCMCHealth, and @CancerLouisiana in New Orleans. Conversations centered around Reticulum Nexus and TrialRelay and how we can work together to connect more cancer patients to clinical trials across Louisiana. #ClinicalTrials #OncologyInnovation #NewOrleans

We moved from theory to real-world proof. 🔬 3,804 patients. F1 = 0.82. 4x faster screening. Published in ESMO Real World Data & Digital Oncology. Neuro-symbolic, multi-agent AI. Not standalone LLMs. Full paper: esmorwd.org/article/S2949-… Press release: massivebio.com/massive-bio-pu… #oncology #AI #clinicaltrials @DrArturoAI @myESMO

We have been nominated at the 30th Annual Webby Awards in the AI - Healthcare and Life Sciences category. 🏆 Top 11% of 13,000+ entries worldwide. Voting is open until April 16th. 🗓️ Your vote helps more cancer patients access clinical trials worldwide. 🌍 vote.webbyawards.com/PublicVoting#/… #WebbyAwards #WebbyNominee #MassiveBio #SYNERGIAI

The Massively Insightful Summit may be over. But the Massively Insightful Podcast is just getting started. 🎙️ Panel discussions on clinical trial access, AI in oncology, and the future of cancer care. A patient story segment that grounded it all. And connections that will last well beyond today. Full panel recordings coming soon to our website and YouTube channel. Stay tuned. Thank you to every speaker, moderator, panelist, and guest who made today possible. 🙏 #MassivelyInsightful #MassiveBio #NexusPulse #OncologyInnovation